Boston Scientific Corporation (BSX) Stock

About Boston Scientific Corporation

Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company's innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Boston Scientific Corporation is led by CEO Michael F. Mahoney, employs 53,000 people, headquartered in Marlborough, US, publicly traded since 1992.

Boston Scientific Corporation (BSX) stock trades at $46.04 with a market capitalization of $68.43B. The stock is valued at a price-to-earnings (P/E) ratio of 22.56, price-to-book of 3.10, price-to-sales of 3.38. Over the past 52 weeks the stock has ranged between $42.29 and $109.50, and currently trades 58.0% below its 52-week high.

On profitability, Boston Scientific Corporation generates a return on equity (ROE) of 14.66%, above the typical market average, return on capital employed of 16.23%, an operating margin of 19.78%, a net profit margin of 17.24%.

In its most recent fiscal year, Boston Scientific Corporation reported annual revenue of $20.1B, net profit of $2.9B, revenue has compounded at 15.2% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.43 — a conservative balance sheet with little leverage risk, a current ratio of 1.62, total assets of $43.7B, $2.0B in cash and equivalents.

BSX has an average daily trading volume of 20,368,178 shares, a beta of 0.56 (less volatile than the overall market).

Official website: www.bostonscientific.com